MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at the 5th Annual Gene Therapy for Ophthalmic Disorders conference, scheduled for September 10-12, 2024, in Boston, Massachusetts. This gathering is a pivotal event for professionals in the biotech and pharmaceutical industries, focusing on the latest innovations in gene therapy for eye diseases.
Dr. Upadhyay will moderate a workshop on September 10, discussing the complexities of navigating regulatory pathways for ophthalmic gene therapies. This session is crucial for understanding the approval processes required to bring new therapies to market. On September 12, he will present on Ocugen’s advancements in gene therapy for ophthalmic disorders, detailing the clinical progress of the company’s modifier gene therapy platform.
“There is tremendous potential for gene therapy to treat both rare retinal diseases and ophthalmic diseases affecting millions,” Dr. Upadhyay stated, emphasizing the importance of ongoing research and collaboration in the field. His participation underscores Ocugen’s commitment to leading-edge research and its role in advancing treatment options for eye disorders.
The conference will bring together over 70 industry leaders to explore breakthroughs in vector engineering, delivery methods, and clinical trial strategies. Attendees will gain insights into optimizing gene therapy approaches for retinal diseases, making it an essential event for those invested in the future of ocular health treatments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.